
David Standring,
Ph.D., has served as senior vice president of biology at Idenix
Pharmaceuticals, Inc. since March 2006. Dr. Standring joined Idenix in 2000 as
executive director of research and development and became vice president,
biology in May 2002. Before joining Idenix, Dr. Standring was affiliated with
Schering Plough Research Institute as an associate director of virology. Prior
to that position he was with Bristol-Myers Squibb Pharmaceutical Research
Institute as group leader of hepatitis, where he was responsible for hepatitis
research programs leading to the filing of Investigational New Drug (IND)
applications and subsequent clinical development of several hepatitis drug
candidates. Before entering the pharmaceutical industry, Dr. Standring was
assistant professor at the University of California at San Francisco where he
pioneered groundbreaking research describing the assembly and replication of
the hepatitis B virus. Dr. Standring holds a Ph.D. in bioorganic chemistry from
Harvard University and a bachelor’s and master’s degree in chemistry from St.
John’s College at the University of Oxford.